WO2008075371A3 - T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation - Google Patents

T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation Download PDF

Info

Publication number
WO2008075371A3
WO2008075371A3 PCT/IL2007/001598 IL2007001598W WO2008075371A3 WO 2008075371 A3 WO2008075371 A3 WO 2008075371A3 IL 2007001598 W IL2007001598 W IL 2007001598W WO 2008075371 A3 WO2008075371 A3 WO 2008075371A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunomodulation
agonist activity
peptide analogs
cxcr4
super
Prior art date
Application number
PCT/IL2007/001598
Other languages
French (fr)
Other versions
WO2008075371A2 (en
Inventor
Amnon Peled
Michal Begin
Katia Beider
Michal Abraham
Original Assignee
Biokine Therapeutics Ltd
Amnon Peled
Michal Begin
Katia Beider
Michal Abraham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd, Amnon Peled, Michal Begin, Katia Beider, Michal Abraham filed Critical Biokine Therapeutics Ltd
Priority to US12/520,811 priority Critical patent/US8663651B2/en
Publication of WO2008075371A2 publication Critical patent/WO2008075371A2/en
Publication of WO2008075371A3 publication Critical patent/WO2008075371A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
PCT/IL2007/001598 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation WO2008075371A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/520,811 US8663651B2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87614506P 2006-12-21 2006-12-21
US60/876,145 2006-12-21

Publications (2)

Publication Number Publication Date
WO2008075371A2 WO2008075371A2 (en) 2008-06-26
WO2008075371A3 true WO2008075371A3 (en) 2009-04-16

Family

ID=39536828

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IL2007/001598 WO2008075371A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
PCT/IL2007/001596 WO2008075369A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
PCT/IL2007/001597 WO2008075370A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IL2007/001596 WO2008075369A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
PCT/IL2007/001597 WO2008075370A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy

Country Status (7)

Country Link
US (5) US8663651B2 (en)
EP (5) EP3011961B1 (en)
CA (2) CA2673719C (en)
ES (1) ES2842210T3 (en)
HK (1) HK1220899A1 (en)
IL (1) IL199468A (en)
WO (3) WO2008075371A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
WO2004020462A1 (en) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4 antagonist and use thereof
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
ES2462517T3 (en) * 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Peptide therapy to increase platelet levels
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
US20140206629A1 (en) * 2011-02-17 2014-07-24 Rhode Island Hospital Stromal Derived Factor Inhibition And CXCR4 Blockade
US9381242B2 (en) * 2011-03-11 2016-07-05 The Chemo—Sero—Therapeutic Research Institute Adjuvant composition containing citrulline
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
KR101419480B1 (en) * 2012-08-03 2014-07-14 가톨릭대학교 산학협력단 A method for mobilization of CD11b+CX3CR1+ cells
WO2014021682A1 (en) * 2012-08-03 2014-02-06 가톨릭대학교 산학협력단 Cd11b+ cx3cr1+ cells, use thereof and method for mass collection of same
WO2016185476A1 (en) * 2015-05-20 2016-11-24 Biokine Therapeutics Ltd. Methods of obtaining mononuclear blood cells and uses thereof
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3368904A1 (en) * 2015-10-30 2018-09-05 Oxford University Innovation Ltd. Peptide and biomarker associated with inflammatory disorders, and uses thereof
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
US11172975B2 (en) 2017-11-17 2021-11-16 Cryoconcepts Lp Portable electro-mechanical cryosurgical device
AU2019375096B2 (en) * 2018-11-09 2024-03-14 Neopep Pharma Gmbh & Co. Kg Polypeptides for the treatment of stress, immunoreaction and stroke syndromes
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008465A1 (en) * 1998-10-05 2006-01-12 Pharmexa A/S Novel methods for therapeutic vaccination

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (en) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
DE3680613D1 (en) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd HUMAN GRANULOXCYT COLONY STIMULATION FACTOR.
EP1018552B1 (en) 1985-08-23 2006-07-05 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3681551D1 (en) 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd HUMAN GRANULOCYTE COLONY STIMULATING FACTOR.
JPH0618778B2 (en) 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment
EP0231819B1 (en) 1986-01-22 1992-04-01 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for the treatment of myelogenous leukemia
ES2039209T5 (en) 1986-01-22 1996-07-16 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOUND THAT PROMOTES THE RESTORATION OF HEMOPOYETIC CAPACITY.
DK203187A (en) 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JPH0725689B2 (en) 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
JP2618618B2 (en) 1988-03-04 1997-06-11 協和醗酵工業株式会社 Anti-G-CSF derivative, ND28 monoclonal antibody
DK174044B1 (en) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptide derived from human granulocyte colony stimulating factor, and method of preparation thereof, DNA encoding said polypeptide, recombinant plasmid containing said DNA, and microorganisms containing said recombinant plasmid .......
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68918331T2 (en) 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Human granulocyte crystalline colony stimulation factor and its production.
CA1339071C (en) 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2989002B2 (en) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
JP3249147B2 (en) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2151283A1 (en) 1993-10-04 1995-04-20 Akiyoshi Matsumoto Polypeptide and anti-hiv agent prepared therefrom
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) * 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
ATE419789T1 (en) 1997-05-23 2009-01-15 Prorhythm Inc HIGH INTENSITY DISPOSABLE FOCUSING ULTRASONIC APPLICATOR
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
DE69914463T2 (en) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
US6178522B1 (en) * 1998-06-02 2001-01-23 Alliedsignal Inc. Method and apparatus for managing redundant computer-based systems for fault tolerant computing
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6576875B1 (en) * 1998-10-27 2003-06-10 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V Method and device for controlling a targeted thermal deposition into a material
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
GB9902399D0 (en) * 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
PL351500A1 (en) 1999-03-29 2003-04-22 Shire Biochem Inc Use of cytidine derivatives for the treatment of leukaemia
AU1488501A (en) 1999-11-24 2001-06-04 Schering Corporation Methods of inhibiting metastasis
AU2001236065A1 (en) 2000-03-03 2001-09-12 Nobutaka Fujii Antiviral compounds
ATE265219T1 (en) 2000-05-09 2004-05-15 Univ British Columbia USE OF CXCR4 ANTAGONISTS TO TREAT CANCER AND AUTOIMMUNE DISEASES
WO2002020561A1 (en) 2000-09-05 2002-03-14 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (en) 2001-02-16 2003-02-10 サンケン電気株式会社 Switching power supply
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8774913B2 (en) * 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
WO2004020462A1 (en) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4 antagonist and use thereof
DE10240064A1 (en) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg Use of chemokine receptor antagonist for treatment of cancer and inhibition of metastasis, functions as ligand for the CXCR4 receptor
JP4666256B2 (en) 2002-12-10 2011-04-06 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004087068A2 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
CA2533753C (en) 2004-03-19 2012-10-16 Morinaga Milk Industry Co., Ltd. Drug for cancer therapy
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
EP1848541A4 (en) 2005-02-07 2013-01-16 Pharmalight Inc Method and device for ophthalmic administration of active pharmaceutical ingredients
JP2009504788A (en) * 2005-08-19 2009-02-05 ジェンザイム・コーポレーション How to strengthen chemotherapy
EP1974018A4 (en) * 2005-12-08 2010-01-27 Univ Louisville Res Found Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
US20080038231A1 (en) * 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
CN101495115A (en) 2006-08-02 2009-07-29 健赞股份有限公司 Combination therapy
WO2008016141A1 (en) 2006-08-04 2008-02-07 Kurume University Kif-derived peptide capable of binding to hla-a24 molecule
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
ES2462517T3 (en) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Peptide therapy to increase platelet levels
EP2443137B1 (en) 2009-06-15 2015-05-20 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008465A1 (en) * 1998-10-05 2006-01-12 Pharmexa A/S Novel methods for therapeutic vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMAMURA, H. ET AL.: "T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.", FEBS LETTERS., vol. 550., 30 July 2003 (2003-07-30), pages 79 - 83 *

Also Published As

Publication number Publication date
WO2008075370A3 (en) 2016-06-09
EP2942059A1 (en) 2015-11-11
EP2094274A2 (en) 2009-09-02
US8455450B2 (en) 2013-06-04
WO2008075371A2 (en) 2008-06-26
WO2008075369A3 (en) 2009-04-09
IL199468A (en) 2017-06-29
EP2104507A2 (en) 2009-09-30
CA2673719A1 (en) 2008-06-26
US8663651B2 (en) 2014-03-04
US20140030211A1 (en) 2014-01-30
CA2673484A1 (en) 2008-06-26
US8765683B2 (en) 2014-07-01
EP3011961A1 (en) 2016-04-27
ES2842210T3 (en) 2021-07-13
EP2104507A4 (en) 2011-05-25
EP2094274A4 (en) 2011-05-11
EP2759302A2 (en) 2014-07-30
CA2673719C (en) 2018-07-24
US20100166715A1 (en) 2010-07-01
WO2008075370A2 (en) 2008-06-26
EP2759302A3 (en) 2014-11-05
US20100184694A1 (en) 2010-07-22
US20120207748A1 (en) 2012-08-16
US20100143334A1 (en) 2010-06-10
HK1220899A1 (en) 2017-05-19
EP3011961B1 (en) 2020-11-11
WO2008075369A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2010146578A3 (en) Peptide therapy for increasing platelet levels
WO2004103390A3 (en) Stable analogs of peptide and polypeptide therapeutics
WO2008153776A8 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
WO2009059325A3 (en) Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
WO2005115306A3 (en) Keratin-binding polypeptides
UA103526C2 (en) Reconstituted surfactant comprising polypeptide analogs of the native surfactant protein sp-b and sp-c
ATE497969T1 (en) CYCLIC ANGIOTENSIN ANALOGUES
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2010085700A3 (en) Treatment for obesity
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
MX353301B (en) Tripeptide compositions and methods for treatment of diabetes.
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2007103739A3 (en) Methods and compositions related to cyclic peptide synthesis
WO2009158238A3 (en) Fibroblast growth factor (fgf) analogs and uses thereof
WO2008113770A3 (en) Anti-androgen peptides and uses thereof in cancer therapy
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
WO2006130718A3 (en) Synthetic peptide inhibitors of thrombin
WO2007143161A3 (en) Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods
WO2010057275A8 (en) Cyclic peptides and uses thereof
EP4218786A3 (en) Opiorphin for use as analgesic agent
WO2008142319A3 (en) Peptide analogues of melanocortin receptors
WO2011014680A3 (en) Gastric inhibitory peptide variants and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849624

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12520811

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07849624

Country of ref document: EP

Kind code of ref document: A2